Li et al., 2009 - Google Patents
Targeted detection of prostate cancer proteins in serum using heavy‐isotope‐labeled‐peptide standards and MALDI‐TOF/TOFLi et al., 2009
- Document ID
- 11210573265251115323
- Author
- Li Y
- Sokoll L
- Rush J
- Meany D
- Zou N
- Chan D
- Zhang H
- Publication year
- Publication venue
- PROTEOMICS–Clinical Applications
External Links
Snippet
Proteins released from cancer tissues to patient sera can potentially be used to achieve sensitive, specific, and early detection of cancer by means of blood tests. In this study, we used a platform that combines glycopeptide capture, heavy‐isotope‐labeled‐peptide …
- 210000002966 Serum 0 title abstract description 76
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Systems analysis of singly and multiply O-glycosylated peptides in the human serum glycoproteome via EThcD and HCD mass spectrometry | |
| Palmblad et al. | Mass spectrometry in clinical proteomics–from the present to the future | |
| CN101600959B (en) | Quantitative methods for peptides and proteins | |
| EP2093569A2 (en) | Compositions and methods for quantification of serum glycoproteins | |
| US20070202539A1 (en) | Methods for quantitative proteome analysis of glycoproteins | |
| CA2934557C (en) | Prostate cancer biomarkers | |
| Karpova et al. | Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives | |
| EP3647788A1 (en) | Biomarker for detecting colorectal cancer | |
| Végvári et al. | Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring | |
| KR101520614B1 (en) | Method for diagnosing cancer based on de-glycosylation of glycoproteins | |
| US8603734B2 (en) | Biomarkers for prostate cancer | |
| Ishihara et al. | Development of quantitative plasma N-glycoproteomics using label-free 2-D LC-MALDI MS and its applicability for biomarker discovery in hepatocellular carcinoma | |
| KR101527283B1 (en) | Method for screening cancer marker based on de-glycosylation of glycoproteins and marker for HCC | |
| WO2015074048A1 (en) | Measurement of gamma-carboxylation of proteins | |
| US8735329B2 (en) | Markers and diagnostic methods for metastasis | |
| Li et al. | Targeted detection of prostate cancer proteins in serum using heavy‐isotope‐labeled‐peptide standards and MALDI‐TOF/TOF | |
| WO2008056290A9 (en) | Use of arylboronic acids in protein labelling | |
| JP6712369B2 (en) | Anti-peptide antibody production method and design method | |
| WO2024133743A1 (en) | Method for diagnosing and/or classifying the severity of a neurodegenerative disease | |
| WO2024235859A1 (en) | Tau assay | |
| Karbassi | The Application of Innovative High-throughput Techniques to Serum Biomarker Discovery | |
| 김용인 | Studies on Lung Cancer Biomarkers by Proteogenomic Analysis | |
| Lang | An LC-MS/MS-based approach for analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using the biomarker prostate-specific antigen (PSA) as example | |
| Castillo | Mass Spectrometry-Based Approaches for Targeted Quantitative Proteomics in Biomarker Development | |
| Kuzmanov | Characterization of Kallikrein 6 N-glycosylation Patterns and Identification of Sialylated Glycoproteins in Ovarian Cancer |